Biotech | August 17, 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
_256_384.png)
MTL, with over 40 years of experience in packaging, caters to the requirements of the FMCG, F&B, homecare, personal care, agrochemicals, pharmaceutical, and liquor industries
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Anti-malaria API facility will be operational in 15-18 months
It’s an AB-rated generic therapeutic version of Durezol
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Subscribe To Our Newsletter & Stay Updated
